Table 1.

Comparison of baseline demographic characteristics of all recruited patients between two drug groups. Age, height and weight of two groups were summarised in Mean ± SE and compared by Student's t test whereas sex were summarised in number (n) and percentage (%) and compared by χ² test

(A) Overall patients (n=123)
Variable	Placebo (n=63) (%)	Umifenovir (n=60) (%)	t/χ2 value	P value
Age (yrs)	47.35 ± 1.96	46.08 ± 1.93	0.46	0.646
Sex:
Female	19 (30.2)	12 (20.0)	1.68	0.195
Male	44 (69.8)	48 (80.0)
Height (cm)	164.86 ± 0.88	165.60 ± 0.81	0.62	0.537
Weight (kg)	69.51 ± 1.02	69.03 ± 1.09	0.32	0.751
(B) Mild-asymptomatic patients (n=82)
Variable	Placebo (n=42) (%)	Umifenovir (n=40) (%)	t/χ2 value	P value
Age (yrs)	45.50 ± 2.45	42.35 ± 2.38	0.92	0.360
Sex:
Female	14 (33)	9 (23)	1.19	0.275
Male	28 (67)	31 (78)
Height (cm)	164.50 ± 1.06	164.25 ± 1.05	0.17	0.867
Weight (kg)	69.19 ± 1.43	68.40 ± 1.43	0.39	0.697

(C) Moderate patients (n=41)
Variable	Placebo (n=21) (%)	Umifenovir (n=20) (%)	t/χ2 value	P value
Age (yrs)	51.05 ± 3.17	53.55 ± 2.61	0.61	0.548
Sex:
Female	5 (24)	3 (15)	0.51	0.477
Male	16 (76)	17 (85)
Height (cm)	165.57 ± 1.61	168.30 ± 1.00	1.42	0.163
Weight (kg)	70.14 ± 1.14	70.30 ± 1.58	0.08	0.936